Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin in systemic right ventricle (DAPA-SERVE)
NCT05717257Phase 4Unknown
- Sponsor
- Monaldi Hospital
- Start
- Aug 2022
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of dapagliflozin in heart failure (HF) (2 arms), sponsored by Monaldi Hospital. Primary endpoints: Adverse Events at 1 year, N-terminal pro-B-type natriuretic peptide at 1 year and 2 more. Status: unknown.
02
Drugs
dapagliflozin
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT05717257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05717257.